Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

August 12, 2026

BSE Limited
Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

National Stock Exchange of India Ltd
Department of Corporate Services
Exchange Plaza, 5th Floor,
C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Further to our intimation dated July 29, 2026, we wish to inform you that the Board of Directors, at its meeting held today, i.e. **August 12, 2026**, has, inter-alia, approved the following:

1. Approved the unaudited standalone and consolidated financial results **(Annexure 1)** and the Limited Review Report of the Company as per Indian Accounting Standards for the quarter ended June 30, 2026 **(Annexure 4)**. We also enclose a Press Release on the results **(Annexure 2)** and an investor presentation **(Annexure 3).**
2. Recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026. The said dividend, if approved at the forthcoming Annual General Meeting (“AGM”), shall be paid on or before October 24, 2026.
3. Approved the Record Date for determining the eligibility of the Shareholders for the purpose of Final Dividend. The same shall be communicated to the Stock Exchanges separately as per the timelines specified under the Listing Regulations.
4. Approved the re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company for a further period of two (2) years, with effect from August 25, 2026, to August 24, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting.
5. Approved the appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company for a period of two (2) years, with effect from August 12, 2026, to August 11, 2028, subject to the approval of the Shareholders at the forthcoming Annual General Meeting. Mr. D. Muralidharan shall continue as the Chief Financial Officer of the Company in addition to him being designated the Whole Time Director.
6. Approved the convening of the 35th Annual General Meeting of the Company on **Friday, September 25, 2026,** through Video Conferencing / Other Audio-Visual means.

The meeting commenced at 10.45 A.M. and concluded at 01.25 P.M.

The details of the change in Directors, in accordance with Regulation 30 of SEBI Listing Regulations read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is enclosed **(Annexure 5)**.

Kindly take the same on your records.

Sincerely Yours
For Caplin Point Laboratories Limited

VENKATRAM GANAPATHISUBRAMANIAN
Digitally signed by VENKATRAM GANAPATHISUBRAMANIAN
Date: 2026.08.12 13:26:26 +05'30'

Venkatram G
General Counsel & Company Secretary
Membership No. A23989
Encl: A/a

ANNEXURE -1

	CAPLIN POINT LABORATORIES LIMITED				
	STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026				
		Quarter Ended			**Year Ended**
	Particulars	**30.06.2026**	**31.03.2026**	**30.06.2025**	**31.03.2026**
		(1)	(2)	(3)	(4)
		(Unaudited)	**(Audited)**	**(Unaudited)**	**(Audited)**
		₹ in Crores			
	Income				
I	Revenue from operations	202.95	191.36	182.57	738.33
II	Other income	62.79	72.39	32.03	195.37
III	**Total Income (I+II)**	**265.74**	**263.75**	**214.60**	**933.70**
IV	**Expenses**				
	a. Cost of materials consumed	42.12	45.80	38.62	158.82
	b. Purchase of traded goods	27.42	24.67	13.18	82.51
	c. Changes in inventories of finished goods, stock in trade and work in progress	(11.38)	(14.89)	6.27	(12.37)
	d. Employee benefits expense	13.73	13.15	9.63	47.72
	e. Finance costs	0.05	0.05	0.04	0.20
	f. Depreciation & Amortisation Expense	6.56	6.90	6.14	25.43
	g. Other Expenses	36.65	39.04	28.26	123.87
	Total Expenses	**115.15**	**114.72**	**102.14**	**426.18**
V	**Profit before exceptional items and Tax (III-IV)**	**150.59**	**149.03**	**112.46**	**507.52**
VI	Exceptional items	-	-	-	-
VII	**Profit Before Tax (V-VI)**	**150.59**	**149.03**	**112.46**	**507.52**
VIII	**Tax Expenses**				
	(1) Current Tax	28.76	26.45	26.91	109.49
	(2) Deferred Tax	1.45	1.77	(0.34)	1.45
	Total Tax Expenses	**30.21**	**28.22**	**26.57**	**110.94**
IX	**Net Profit for the period (VII-VIII)**	**120.38**	**120.81**	**85.89**	**396.58**
X	**Other Comprehensive Income / (Loss) - Net of Tax**				
	A. Items that will not be re-classified to profit or loss				
	i) Remeasurements of Defined Benefit Plan	-	(0.17)	-	(0.09)
	ii) Income tax relating to these items	-	0.04	-	0.02
XI	**Total Comprehensive Income For The Period (IX+X)**	**120.38**	**120.68**	**85.89**	**396.51**
XII	Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.20	15.20
XIII	Other equity				2,035.30
XIV	**Earnings Per Share (EPS) of Face value Rs 2/- per Equity share***				
	(a) Basic (in Rupees)	**15.84**	**15.89**	**11.30**	**52.17**
	(b) Diluted (in Rupees)	**15.79**	**15.85**	**11.26**	**52.02**
		***(Not Annualised)**	***(Not Annualised)**	***(Not Annualised)**	***(Annualised)**
	See Accompanying notes to Financial Results				

BRAHMAYYA & CO. * CHARTERED ACCOUNTANTS * For Identification Only

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED

Standalone Notes:

1) The above Unaudited Standalone financial Results for the Quarter ended June 30, 2026 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026 and reviewed by the Statutory Auditors.

2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company.

4) Other Income and Profit Before Tax includes:

₹ In Crores

	Quarter Ended			Year Ended
Particulars	**30.06.2026**	**31.03.2026**	**30.06.2025**	**31.03.2026**
Dividend from wholly owned subsidiary Caplin Point Far East Limited	28.90	30.55	8.12	62.30

5) Details of number of shares allotted under Employee Stock Option Plan (ESOP):

Number of Shares

	Quarter Ended			Year Ended
Particulars	**30.06.2026**	**31.03.2026**	**30.06.2025**	**31.03.2026**
Shares Alloted under Employee Stock Option Plan (ESOP)	-	-	-	-
Total Number of Equity Shares of the Company	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696

6) The Board of Directors at their meeting held on 14th May, 2026 declared an interim dividend of ₹4.00 (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on 8th June 2026. The Board of Directors at their meeting held today have recommended a final dividend of ₹...4.../- per equity share (200%) for the financial year 2025-26 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company.

The total dividend for the financial year 2025-26 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be ₹..8../- per equity share (400%) of the face value of ₹ 2 each.

7) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.

BRAHMAYYA & CO. For Identification Only CHARTERED ACCOUNTANTS

For and on behalf of the Board

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

Place: Chennai
Date: August 12, 2026

Dr. Sridhar Ganesan
Managing Director

	CAPLIN POINT LABORATORIES LIMITED				
	STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026				
		Quarter Ended			Year Ended
	Particulars	30.06.2026	31.03.2026	30.06.2025	31.03.2026
		(1)	(2)	(3)	(4)
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		₹ in Crores			
	Income				
I	Revenue from operations	610.36	600.16	510.22	2,187.19
II	Other income	33.55	28.36	23.14	115.54
III	**Total Income (I+II)**	**643.91**	**628.52**	**533.36**	**2,302.73**
IV	**Expenses**				
	a. Cost of materials consumed	107.06	102.11	90.20	357.20
	b. Purchase of traded goods	196.36	209.02	96.81	572.20
	c. Changes in inventories of finished goods, stock in trade and work in progress	(58.22)	(66.13)	8.23	(63.72)
	d. Employee benefits expense	54.13	52.62	43.16	199.15
	e. Finance costs	0.18	0.36	0.18	0.87
	f. Depreciation & Amortisation Expense	21.62	18.80	16.29	72.77
	g. Other Expenses	97.55	98.30	94.06	361.51
	Total Expenses	**418.68**	**415.08**	**348.93**	**1,499.98**
V	**Profit before share of profit in Associate, Exceptional Items and tax (III-IV)**	**225.23**	**213.44**	**184.43**	**802.75**
VI	Share of Profit/(Loss) in Associate	(0.01)	(0.00)	0.03	0.04
VII	Exceptional items	-	-	-	-
VIII	**Profit Before Tax (V+VI+VII)**	**225.22**	**213.44**	**184.46**	**802.79**
IX	**Tax Expenses**				
	(1) Current Tax	46.18	41.02	33.10	146.29
	(2) Deferred Tax	(0.05)	(0.46)	0.60	6.77
	Total Tax Expenses	**46.13**	**40.56**	**33.70**	**153.06**
X	**Net Profit for the period (VIII - IX)**	**179.09**	**172.88**	**150.76**	**649.73**
XI	**Other Comprehensive Income - Net of Tax**				
	A. Items that will not be re-classified to profit or loss				
	i) Remeasurements of Defined Benefit Plan	-	(0.10)	-	0.29
	ii) Income tax relating to these items	-	0.03	-	(0.07)
	B. Items that will be re-classified to profit or loss				
	i) Exchange difference in translating the financial statements of foreign operations	(1.86)	76.97	0.36	141.42
XII	**Total Comprehensive Income For The Period (X + XI)**	**177.23**	**249.78**	**151.12**	**791.37**
XIII	**Profit attributable to:**				
	Owners of the Company	176.91	170.11	152.80	641.24
	Non - controlling interests	2.18	2.77	(2.04)	8.49
		179.09	**172.88**	**150.76**	**649.73**
XIV	**Total Comprehensive Income For The Period attributable to**				
	Owners of the Company	175.05	247.01	153.16	782.88
	Non - controlling interests	2.18	2.77	(2.04)	8.49
		177.23	**249.78**	**151.12**	**791.37**
XV	Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.20	15.20
XVI	Other equity excluding Non-controlling interest				3,571.22
XVII	**Earnings Per Share (EPS) of Face value Rs 2/- per Equity share***				
	(a) Basic (in Rupees)	**23.27**	**22.38**	**20.10**	**84.36**
	(b) Diluted (in Rupees)	**23.21**	**22.31**	**20.03**	**84.11**
		*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)

BRAHMAYYA & CO. CHARTERED ACCOUNTANTS For Identification Only

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED

Segment Information (Consolidated)

Particulars	Quarter Ended			Year Ended
	30.06.2026	31.03.2026	30.06.2025	31.03.2026
	(1)	(2)	(3)	(4)
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	₹ in Crores			
1) Segment revenue (Total Revenue)				
Rest of the World	476.07	470.25	403.53	1,733.79
USA	134.29	129.91	106.69	453.40
Unallocated	33.55	28.36	23.14	115.54
Total	**643.91**	**628.52**	**533.36**	**2,302.73**
2) Segment results (PBT)				
Rest of the World	158.40	163.32	151.46	631.20
USA	33.27	21.76	9.86	56.05
Unallocated	33.55	28.36	23.14	115.54
Total	**225.22**	**213.44**	**184.46**	**802.79**
3) Segment Assets				
Rest of the World	2,021.21	1,918.28	1,488.80	1,918.28
USA	672.75	656.00	587.19	656.00
Unallocated	1,502.39	1,471.20	1,236.99	1,471.20
Total	**4,196.35**	**4,045.48**	**3,312.98**	**4,045.48**
4) Segment Liabilities				
Rest of the World	350.80	332.52	249.31	332.52
USA	69.79	82.16	50.34	82.16
Unallocated	-	-	-	-
Total	**420.59**	**414.68**	**299.65**	**414.68**

BRAHMAYYA & CO. ★ CHARTERED ACCOUNTANTS ★ For Identification Only

CAPLIN POINT LABORATORIES LTD. ★ CHENNAI 600 096.

CAPLIN POINT LABORATORIES LIMITED

Consolidated Notes:

1) The above Unaudited Consolidated Financial Results for the quarter ended June 30, 2026, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on August 12, 2026 and reviewed by the Statutory Auditors.

2) The Unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3) The Group is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results.

4) Details of number of shares allotted under Employee Stock Option Plan (ESOP):

	Number of Shares			
	Quarter Ended			Year Ended
Particulars	**30.06.2026**	**31.03.2026**	**30.06.2025**	**31.03.2026**
Shares Allotted under Employee Stock Option Plan (ESOP)	-	-	-	-
Total Number of Equity Shares of the Company	7,60,11,696	7,60,11,696	7,60,11,696	7,60,11,696

5) The Board of Directors at their meeting held on 14th May, 2026 declared an interim dividend of ₹4.00 (Rs. Four Only) per equity share (200 %) for the financial year 2025-26 and was paid to the shareholders on 8th June 2026. The Board of Directors at their meeting held today have recommended a final dividend of ₹..4.../- per equity share (200%) for the financial year 2025-26 which is subject to approval of the Shareholders in the ensuing Annual General Meeting of the Company.

The total dividend for the financial year 2025-26 including the final dividend (subject to the approval of the Shareholders at the ensuing Annual General Meeting) will be ₹..8../- per equity share (400%) of the face value of ₹ 2 each.

6) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

BRAHMAYYA & CO. CHARTERED ACCOUNTANTS
For Identification Only

CAPLIN POINT LABORATORIES LTD. CHENNAI 600 096.

For and on behalf of the Board

Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: August 12, 2026

Q1 FY27 Total revenue at ₹644 Crores; an increase of 20.7% YoY

Q1 FY27 PAT at ₹179 Crores; an increase of 18.8% YoY

US Market Q1 FY27 Total Revenue ₹137 Crores; an increase of 26% YoY

Free Cash Reserves at ₹1,502 Crores; Liquid Assets at ₹2,875 Crores.

Chennai, 12th August 2026: Caplin Point Laboratories Ltd. ("Caplin Point" or the "Company") (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter ended June 30, 2026.

Consolidated Financial Performance for Q1 FY27:

₹ in Crores

Particulars	Q1 FY 27	Q1 FY 26	YoY (%)	Q4 FY 26	QoQ (%)	*12M FY26*	*12M FY25*	YoY (%)
Revenue from Operations	610.4	510.2	19.6%	600.2	1.7%	2,187.2	1,937.5	12.9%
Total Revenue	643.9	533.4	20.7%	628.5	2.4%	2,302.7	2,033.9	13.2%
Gross Profit	365.2	315.0	15.9%	355.2	2.8%	1,321.5	1,166.6	13.3%
Gross Margin %	*59.8%*	*61.7%*		*59.2%*		*60.4%*	*60.2%*	
EBITDA	247.0	200.9	23.0%	232.6	6.2%	876.4	743.4	17.9%
EBITDA Margin %	*38.4%*	*37.7%*		*37.0%*		*38.1%*	*36.5%*	
Profit Before Tax	225.2	184.5	22.1%	213.4	5.5%	802.8	676.8	*18.6%*
PBT Margin %	*35.0%*	*34.6%*		*34.0%*		*34.9%*	*33.3%*	
Profit after Tax	179.1	150.8	18.8%	172.9	3.6%	649.7	541.1	20.1%
PAT Margin	*27.8%*	*28.3%*		*27.5%*		*28.2%*	*26.6%*	

Other Consolidated Financial Highlights for Q1 FY 27:

- Gross Margin stands at 59.8% for Q1 FY27 as compared to 61.7% in Q1 FY26.
- EBITDA Margin for Q1 FY27 is at 38.4% vs 37.7% in Q1 FY26.
- Basic EPS increased by 15.8% to ₹23.27 in Q1 FY27 compared to ₹20.10 in Q1 FY26.
- Cash Flow from Operations in Q1 FY27 is ₹95 Crores vs ₹118 Crores in Q1 FY26.
- Free Cash Flow is ₹40 Crores (after Capex investment of ₹55 Crores) in Q1 FY27 as compared to ₹53 Crores (after capex investment of ₹65 Crores) in Q1 FY26.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for Q1 FY27 is in the range of 78% and 22% respectively.
- CSL's Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for Q1 FY27 in the range of 85% and 15% respectively.
- As of 30th June 2026, Inventories are at ₹505 Crores - 47% Stock at the warehouses, close to the customer; In Transit 23%; 30% in India. Receivables stood at 128 days.
- As of 30th June 2026, Free Cash reserves are at ₹1,502 Crores and Total Liquid Assets at ₹2,875 Crores.

Business Highlights for Q1 FY27:

Emerging Markets:

- Caplin continues steady and consistent growth in Latin America across all geographies and segments.
- Company has won emergency tenders across Central America to the tune of $7 million, to be supplied over next 2 Quarters.
- Chile Update – Company shows consistent growth in Private and Tender market sales in Chile. Company has won tenders to the tune of $12 million to be supplied over the next 18 months.
- Mexico Update – Company has received 4 additional product approvals in Mexico and plans are underway to launch these products in the coming months. The company is working on a pipeline of 120+ products to be filed in the next 18 months, in addition to the 29 approvals received.
- Oncology Unit update – Caplin One Labs oncology facility in Kakkalur, which has successfully undergone its first Regulatory inspection, completes submission batches for 6 products. Additionally, 18 products submission batches are planned in the next 12 months, for LatAm, US and EU markets.
- Caplin's API unit in Vizag for General Category products completed scale up for 6 APIs, all to be used for backward integration for its US and LatAm formulations. Company aims to file the first few DMFs from this site in 2026/27.
- Caplin's Oncology API unit in Thervoy, TN, will be completed by Q3/Q4-FY27, with first DMFs filed from this plant in the following year.
- Construction ongoing at full swing for Company's new project involving OSD and Dermatology divisions in Pondy. The facility is aimed at expansion of capacities by over 2X of the existing capacities. This facility is aimed at meeting growing capacity demand in existing markets and also entry into Regulated markets for these dosages.
- Amaris Clinical update – To cater to growing demands for internal pipeline products BE and Clinical studies, Company takes up expansion activities at Amaris Clinical to increase capacity up to 120 Beds. Project is expected to be completed by end of FY27.

US & Regulated Markets:

- Caplin Steriles Limited (CSL) continues to show robust growth across all parameters. Split between B2B and B2C revenues currently at 70/30.
- Company has 60 ANDAs approved and 5 under review, of which 50 were internally developed and 15 acquired from outside. Company has a pipeline of another 40+ products under filing or advanced stage of development.
- CSL has filed 110+ products (of which 65 are approved) in multiple Non-US markets, such as Canada, EU, Australia, Mexico, Brazil, South Africa, Saudi, UAE etc. Plans in place to file 60+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27 / FY28.
- Company has launched 38 products in the US till date, with plans to launch 12 more products in FY27.
- CSL plans to file its first Pre-Filled Syringe (PFS) product from the site within FY27, with a larger pipeline of 14+ PFS products to be filed in FY28.
- Company's move towards being completely digitalized gains momentum with the automation of all physical logbooks to e-logbooks shortly, followed by overall batch manufacturing records to be in

electronic format as well after that. Company has already achieved total automation in Quality Control and Microbiology areas at the site.

- To cater to the growing capacity needs at CSL, company's COL-II facility construction will be completed by Mar '27 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction.

- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**
  - CSU continues excellent momentum under its own label in the US, with 33 product launches till date. Company plans to launch another 10 products in the US in FY27.
  - CSU has added multiple direct sales contracts with large and small IDNs, in addition to the major Wholesalers in the US.
  - Company sees steady and consistent market share growth across 90% for all launched products in the US. CSU aims to meaningfully grow market share without erosion of bottom line.

Commenting on the Q1-FY27 performance, Mr. C.C. Paarthipan, Chairman said:

We are pleased to begin FY27 on a strong and encouraging note, with the Company delivering healthy growth across both our Emerging Markets and the US, while continuing to strengthen the foundations for sustainable long-term growth. Our Q1 performance reflects the consistency of our strategy, the resilience of our business model and the disciplined execution across our expanding portfolio and geographies. The continued momentum in Latin America, the accelerating contribution from the US, and the progress across our manufacturing, R&D and backward-integration initiatives reinforce our confidence in the opportunities ahead. At the same time, our strong balance sheet and substantial liquidity provide us with the flexibility to continue investing in capacity, capabilities and new markets. As we move forward, our focus remains firmly on building a more integrated, diversified and future-ready pharmaceutical platform, while creating enduring value for all our stakeholders.

Caplin Point Laboratories Limited

Strategic Growth Initiatives

Project Summary					
Facility	**Location**	**Product**	**Target Market**	**Status**	**Timeline**
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity Completed	Q4 FY27
OSD Facility	Puducherry	Oral Solid Dosages	New Markets such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmic	Regulated Markets	Civil & Structural activity ongoing at full swing	Q1 FY28

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.

Tamil Nadu, India



Andhra Pradesh, India

Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes "Asia's 200 Best Under a Billion" list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded "The Emerging Company of 2018" by Economic Times Family Business Awards.

For further information, please contact:

G Venkatram,
General Counsel & Company Secretary
Caplin Point Laboratories Limited

+91 44 2496 8000
investor@caplinpoint.net

Simran Malhotra / Soham Arora
Churchgate Partners

+91 99454 72589
caplinpoint@churchgatepartners.com

Caplin Point
Laboratories Limited

EARNINGS PRESENTATION Q1 FY27

Rated #1 in India for "*Most Consistent Profitable Growth across the last 10 years*"

*Second Largest wealth creator for the decade ending 2020**

Aug 2026 | www.caplinpoint.net

#Value Research magazine – Wealth Insight June 2022 issue
*The Economic Times

Evolution Over the Decades

Caplin Point Laboratories Limited

- **1990** – Incorporation
- **1994** – Listed on Stock Exchange
- **2001** – Entered Angola with unique Stock & Sale model
- **2005** – Started outsourcing from China
- **2006** – Entered the Caribbean and Latin America
- **2014** – Work on Regulated Markets Injectable unit starts
- **2017** – Liquid injectable facility gets EU & USFDA Approval
- **2018** – Started first commercial shipments to US
- **2019** – Fidelity investment into Caplin Steriles
- **2021** – Rs. 600 Cr. Expansion, CRO wing Amaris Clinical gets USFDA approval
- **2022** – Acquires API plant in Vizag, as part of backward integration move. Amaris Clinical gets ISP Chile approval
- **2023** – Incorporates Caplin Steriles USA Inc for launching own label in US
- **2024** – Oncology facility started production at SIDCO Kakkalur, Chennai
- **2025** – CSU commencement of operations
- **2026** – Acquires 10 ANDAs; receives multiple USFDA approvals. Chile subsidiary starts commercial operation

Contract manufacturer	Becoming a responsible pharma company	Diversified Product Portfolio
Market-led Company	Technology and research-led marketing Company	5,000+ Products registered and 650+ Pharmaceutical formulations
Plain vanilla generic products	Mix of generics, branded generics and speciality molecules and Injectables	36 Therapeutic Segments
Introducing products that plugged marketplace gaps	Launch speciality niche products that Create new markets in varied therapy segments	Product mix covers over 65% of WHO essential drug list
Negative-working capital business	Selective use of Credit strategy to increase market share and remain cash surplus	Latest focus towards complex spaces
2 main geographies 10 countries (Latin America & Francophone Africa)	Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly	Accounts for larger shelf share across pharmacies on account of a widening product basket

Q1 FY27 Income Statement

Caplin Point Laboratories Limited

Revenue from Operations



Gross Profit



EBITDA



EBIT



PAT



Earnings Per Share



(All figures in Rs. Crores except EPS in Rs.)

Q1 FY27 Profit Margins

Caplin Point
Laboratories Limited

Gross Profit Margins (%)



EBITDA Margins (%)



EBIT Margins (%)



PAT Margins (%)



FY26 Income Statement

Caplin Point
Laboratories Limited

Revenue from Operations



Gross Profit



EBITDA



EBIT



PAT



Profit Margins



(All figures in Rs. Crores)

Leadership Team

Caplin Point
Laboratories Limited

Chairman Perspectives

Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

" We are pleased to begin FY27 on a strong and encouraging note, with the Company delivering healthy growth across both our Emerging Markets and the US, while continuing to strengthen the foundations for sustainable long-term growth. Our Q1 performance reflects the consistency of our strategy, the resilience of our business model and the disciplined execution across our expanding portfolio and geographies. The continued momentum in Latin America, the accelerating contribution from the US, and the progress across our manufacturing, R&D and backward-integration initiatives reinforce our confidence in the opportunities ahead. At the same time, our strong balance sheet and substantial liquidity provide us with the flexibility to continue investing in capacity, capabilities and new markets. As we move forward, our focus remains firmly on building a more integrated, diversified and future-ready pharmaceutical platform, while creating enduring value for all our stakeholders."

Management Team

Dr. Sridhar Ganesan

- Managing Director

Mr. D Muralidharan

- Chief Financial Officer

Q1 FY27 Highlights (Emerging Markets)

Caplin Point
Laboratories Limited

Emerging Markets Business Highlights

01

Caplin continues steady and consistent growth in Latin America across all geographies and segments

02

Caplin has won emergency tenders across Central America to the tune of $7 million, to be supplied over the next few Quarters

03

Chile Update – Company shows consistent growth in Private and Tender market sales in Chile. Company has won tenders to the tune of $12 million to be supplied over the next 18 months

04

Mexico Update – Company has received 4 additional product approvals in Mexico and plans are underway to launch these products in the coming months. The company is working on a pipeline of 120+ products to be filed in the next 18 months

05

Oncology Unit update – Caplin One Labs oncology facility in Kakalur, which has successfully undergone its first Regulatory inspection, completes submission batches for 6 products. Additionally, 18 products submission batches are planned in the next 12 months

06

Caplin's API unit in Vizag for General Category products completed scale up for 6 APIs, all to be used for backward integration for its US and LatAm formulations. Company aims to file the first few DMFs from this site in 2026/27

07

Caplin's Oncology API unit in Thervoy, TN, will be completed by Q3/Q4-FY27, with first DMFs filed from this plant in the following year

08

Construction ongoing at full swing for Company's new project involving OSD and Dermatology divisions in Pondy. The facility is aimed at expansion of capacities by over 2X of the existing capacities

09

The OSD and Dermatology divisions in Pondy facility is aimed at meeting growing capacity demand in existing markets and also entry into Regulated markets for these dosages

10

Amaris Clinicals update – To cater to growing demands for internal pipeline products BE and Clinical studies, Company takes up expansion activities at Amaris Clinicals to increase capacity up to 120 Beds. Project is expected to be completed by end of FY27

Q1 FY27 Highlights (US and Regulated markets)

Caplin Point Laboratories Limited

01

Caplin Steriles Limited (CSL) continues to show robust growth across all parameters. Split between B2B and B2C revenues currently at 70/30

02

Company has 60 ANDAs approved and 5 under review, of which 50 were internally developed and 15 acquired from outside. Company has a pipeline of another 40+ products under filing or advanced stage of development

03

CSL has filed 110+ products (of which 65 are approved) in multiple Non-US markets. Plans in place to file 60+ products in these regions in the next 18 months. Meaningful revenue is expected out of these markets in FY27 / FY28

04

Company has launched 38 products in the US till date, with plans to launch 12 more products in FY27

05

CSL plans to file its first Pre-Filled Syringe (PFS) product from the site within FY27, with a larger pipeline of 14+ PFS products to be filed in FY28

US and Regulated Markets Business Highlights

06

Company's move towards being completely digitalized gains momentum with automation of all physical logbooks, followed by overall batch manufacturing records to be in electronic format. Has already achieved total automation in Quality Control and Microbiology areas at the site

07

To cater to the growing capacity needs at CSL, company's COL-II facility construction will be completed by Mar '27 to house 5 Injectable, Ophthalmic and BFS lines. Provision to add 3 more lines also included in the construction

08

CSU continues excellent momentum under its own label in the US, with 33 product launches till date. Company plans to launch another 10 products in the US in FY27

09

CSU has added multiple direct sales contracts with large and small IDNs, in addition to the major Wholesalers in the US

10

Company sees steady and consistent market share growth across 90% for all launched products in the US. CSU aims to meaningfully grow market share without erosion of bottom line

Research & Development Capabilities

Caplin Point
Laboratories Limited

1. Caplin has 5 dedicated R&D setups (3 – DSIR approved).
2. Continuous capex investment of over Rs. 870 Cr over last 5 years towards enhanced manufacturing and R&D capabilities, from internal accruals.
3. Total R&D Spends (Capex + Opex) is 15.5% of FY26 PAT.
4. Caplin ranks amongst the top companies in India, for R&D spend as a percentage of Revenue on average in the past 5 years.*
5. Completed R&D for 90+ APIs to be used for backward integration in US and Emerging markets. First DMF filing targeted by end of FY2027.



387
Strength of R&D Team



FY 2012



Research and Development along with conscious conversion of certain fast-selling generics into Branded Generics for better profitability

FY 2026



Generics Branded Generics

*Source – CNBC-TV18, Dec 31st 2020

*Including Partners and Bought Out

Revenue Break up and Manufacturing Strategy

Caplin Point
Laboratories Limited

FY26 Operating Revenue



Revenue by Business Segment (Emerging Markets)



Revenue by Channel (Emerging Markets)



Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,303 Cr in FY26

Manufacturing & Outsourcing



Exports



Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Generics and Branded Generics Product Mix

Caplin Point
Laboratories Limited

Non-Steroidal Antiinflammatory Drugs-NSAIDS

Antihelminthics/ Dewormer

Analgesic

Antibiotic and Antifungal

Antihypertensive drug

Electrolytes

Caplin Point Structure

Caplin Point Laboratories Limited

Caplin Point Laboratories Ltd (BSE: 524742| NSE: CAPLIPOINT)

Manufacturing Units:
- CP I: Puducherry
- CP X: Vishakhapatnam

Research & Development:
- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: Formulation R&D, Perungudi, Chennai

Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

Caplin Point Far East Ltd

Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

Caplin One Labs Ltd (COL)

Manufacturing Unit:
- SIDCO, Kakkalur (Near Chennai)

Caplin Steriles Ltd (India)

Manufacturing Units:
- CP IV: Gummidipoondi

Research & Development:
- Perungudi, Chennai
- Gummidipoondi

- Sunsole Solar Private Ltd (Associate of CSL)

Caplin Steriles USA Inc (US)

Distribution:
- Front-end trading arm for the sale of products in the USA

Manufacturing and R&D Platform



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

Note. CP III, CP VI and CP VII are for Research and Development

CP I
Puducherry

CP III
Chengalpattu

CP IV
Gummidipoondi

CP VI
Hyderabad

Corporate Office and other R&D units:
Chennai

CP VII
Chennai

Strategic Investments

Caplin Point
Laboratories Limited

Project Summary					
Facility	**Location**	**Product**	**Target Market**	**Status**	**Timeline**
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity completed	Q4 FY27
OSD Facility	Puducherry	Oral Solid Dosages	New Market such as Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q1 FY28
COL Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmic	Regulated Markets	Civil & Structural activity ongoing at full swing	Q1 FY28

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process

Caplin Point's Investment Case

Caplin Point Laboratories Limited

Core Business to show consistent growth	Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows
US Business to Boost the Growth	Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth
Backed by Enhanced Value Chain	Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings
Strong Balance Sheet	Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision
Expansion into Other Geographies and Widening of the Portfolio	Caplin plans to enter more regulated markets such as Canada, Australia, MENA as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

Experienced and Visionary Board of Directors (1/2)

Caplin Point Laboratories Limited

Mr. C.C. Paarthipan

Chairman

30+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid

Dr. Sridhar Ganesan

Managing Director

35+ Years experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS

Mr. Ashok Partheeban

Vice Chairman

23+ Years experience in Pharmaceutical Industry

Oversees the entire LATAM operations since 2002 as well as other emerging markets

Spearheaded market expansion and growth initiatives in the LATAM region

Holds an Associate's Degree in OPM from Harvard Business School and a Bachelor's in Marketing from Middlesex University

Mr. Vivek Partheeban

Vice Chairman

20+ years of experience in the pharmaceutical industry

Was COO at Caplin Point Laboratories Ltd, Oversees the entire U.S/regulated market. operations

Educated at Harvard Business School and Monash University

Honorary Consul for the Republic of Guatemala in Chennai since 2018

Dr. KC John

Independent Director

35+ years of experience in sustainable development

Held leadership roles in start-ups, tech ventures, and acquisitions

Expert for Tamil Nadu Industrial Development Corporation

Doctorate in Management from Indian Institute of Management, Ahmedabad

Experienced and Visionary Board of Directors (2/2)

Caplin Point Laboratories Limited

Dr. R Nagendran

Independent Director

Ph.D in Ecology and Ethology and M.SC in Zoology

Former Expert Member of the National Green Tribunal and former Head of Department of Environmental Science in St. Joseph's College, Bangalore.

Mr S Deenadayalan

Independent Director

Post Graduate degree in Social Work from Madras School of Social Work and Under Graduate degree in Sociology from Annamalai University

Has extensively worked and mentors individuals enabling them to become successful professionals and more than 30,000 municipal school students have been benefitted by his idealistic model.

Mr. R. Vijayaraghavan

Independent Director

35+ years of experience as a taxation expert with consulting and litigation practice across India

Advises major corporate groups in South India on Direct Taxes, Tax Planning, Tax Litigations

Specializes in advising on taxation of non-residents, joint ventures & collaborations, double taxation avoidance agreements & transfer pricing issues.

Mrs. Susan Mathew

Independent Director

Post Graduate degree from Union Christian College and Graduate of Women's Christian College, Chennai

Served 36 years in senior IAS positions, including as Principal Secretary to the Governor

She contributed to key policies like private power projects and the Comprehensive Transport Policy in Tamil Nadu

Q1 FY27 Consolidated Income Statement

Caplin Point Laboratories Limited

In Rs. Crores

Particulars	Q1 FY27	Q1 FY26	*YoY (%)*	Q4 FY26	*QoQ (%)*	FY26	FY25	*YoY (%)*
Revenue from Operations	610.36	510.22	19.6%	600.16	1.7%	2,187.19	1,937.47	*12.9%*
Other Income	33.55	23.14	45.0%	28.36	18.3%	115.54	96.43	
Total Revenue	**643.91**	**533.36**	**20.7%**	**628.52**	**2.4%**	**2,302.73**	**2,033.90**	***13.2%***
Cost of Goods sold	245.20	195.24	25.6%	245.00	0.1%	865.68	770.84	*12.3%*
Gross Profit (Excluding Other Income)	**365.16**	**314.98**	**15.9%**	**355.16**	**2.8%**	**1,321.51**	**1,166.63**	***13.3%***
Gross Profit Margin (on Rev from Operations)	***59.8%***	***61.7%***		***59.2%***		***60.4%***	***60.2%***	
Employee Benefit Expenses	54.13	43.16	25.4%	52.62	2.9%	199.15	184.63	*7.9%*
Research and Development expenses	21.30	17.96	18.5%	19.94	6.8%	79.89	76.68	*4.2%*
Other operating expenses	76.25	76.10	0.2%	78.36	(2.7%)	281.62	258.39	*9.0%*
Total expenditure	**151.68**	**137.22**	**10.5%**	**150.92**	**0.5%**	**560.66**	**519.70**	***7.9%***
EBITDA	**247.03**	**200.90**	**23.0%**	**232.60**	**6.2%**	**876.39**	**743.36**	***17.9%***
EBITDA Margin	*38.4%*	***37.7%***		***37.0%***		*38.1%*	*36.5%*	
Depreciation and Amortisation	21.62	16.29	32.8%	18.80	15.0%	72.77	65.96	*10.3%*
EBIT	**225.41**	**184.61**	**22.1%**	**213.80**	**5.4%**	**803.62**	**677.40**	***18.6%***
EBIT Margin	***35.0%***	***34.6%***		***34.0%***		***34.9%***	***33.3%***	
Finance Cost	*0.18*	*0.18*		*0.36*		0.87	0.61	
Share of Profit/(Loss) in associates	*(0.01)*	*0.03*		*(0.00)*		*0.04*	*(0.01)*	
Profit Before Tax	**225.22**	**184.46**	***22.1%***	**213.44**	***5.5%***	**802.79**	**676.78**	***18.6%***
PBT Margin	***35.0%***	***34.6%***		***34.0%***		***34.9%***	***33.3%***	
Tax	46.13	33.70	*36.9%*	40.56	*13.7%*	153.06	135.69	*12.8%*
Profit after Tax	**179.09**	**150.76**	***18.8%***	**172.88**	***3.6%***	**649.73**	**541.09**	***20.1%***
PAT Margin	***27.8%***	***28.3%***		***27.5%***		***28.2%***	***26.6%***	

ESG and CSR

Caplin Point Laboratories Limited

ESG Commitments

Community Development
- ✓ Caplin Group's state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai

Recycled Waste
- ✓ 60.2 MT waste recycled in 2025

Environmental &Social
- ✓ Low carbon footprint
- ✓ Women empowerment
- ✓ Investments in rural healthcare

CSR

INR 4.16 Crores
Amount spent on CSR in FY26

INR 0.68 Crores
Amount spent on CSR in Q1FY27

Disclaimer

Caplin Point Laboratories Limited

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

Caplin Point
Laboratories Limited

Mr G Venkatram

investors@caplinpoint.net

Churchgate
Investor Relations

Simran Malhotra / Soham Arora

+91 99454 72589

caplinpoint@churchgatepartners.com

BSE 524742 NSE CAPLIPOINT

CIN: L24231TN1990PLC019053

ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET

Brahmayya&co.
Chartered Accountants

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Caplin Point Laboratories Limited

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Caplin Point Laboratories Limited ("the Company")**, for the quarter ended 30^{th} June 2026 (**"the Statement"**), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

2. The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing, and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the Statement prepared in accordance with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No. 000511S

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575UXZBK05311

Place: Chennai
Date: August 12, 2026

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Caplin Point Laboratories Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Caplin Point Laboratories Limited ("the Holding Company")**, and its subsidiaries (the Holding Company and its subsidiaries together referred to as "**the Group**") and its share in the net profit / (loss) after tax and total comprehensive income / loss of associate for the quarter ended 30th June 2026 ("**the Statement**") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

2. The Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

   Subsidiary Companies

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary
Caplin One Labs Limited, India *(Formerly known as Caplin Onco Limited)*	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary

48, Masilamani Road, Balaji Nagar,
Royapettah, Chennai - 600 014. India.
T : +91 - 044 - 2813 1128 / 38 / 48 / 58
E : mail@brahmayya.com | www.brahmayya.com

Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary
Neoethicals Chile SpA, Chile	Step Down Subsidiary
Triwin Pharma S.A DE C.V Mexico, Mexico	Step Down Subsidiary

Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

Associate Company of Caplin Steriles Limited

Name of the Entity	Relationship
Sunsole Solar Private Limited, India	Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim results of five subsidiaries and eight step-down subsidiaries included in the Statement, whose interim financial results reflect total revenues of INR 591.51 crores, total net profit after tax of INR 104.98 crores, and total comprehensive income of INR 77.15 Crores for the quarter ended 30th June 2026, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and step-down subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in Paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

7. The Statement includes the interim financial results of one step-down subsidiary, which have not been reviewed by their auditors, whose interim financial results reflect total revenues of INR 0.06 crores, total net loss after tax of INR 1.22 crores and total comprehensive income of INR 1.22 crores for the quarter ended 30th June 2026, as considered in the Statement. The Statement also includes the Group's share of net loss after tax of INR 0.01 crores, and total comprehensive loss of INR 0.01 crores for the quarter ended 30th June 2026, in respect of an associate, based on their interim financial results which have not been reviewed by their auditor. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.

For Brahmayya & Co.,
Chartered Accountants
Firm Registration No. 000511S

BRAHMAYYA & CO. CHENNAI INDIA CHARTERED ACCOUNTANTS

N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575LELFKT9011

Place: Chennai
Date: August 12, 2026

Caplin Point Laboratories Limited
Regd. office: Ashvich Tower, 3rd Floor,
No.3, Developed Plots Industrial Estate, Perungudi, Chennai – 600096.
Phone : +91 44 24968000 / +91 80127 72888 / +91 44 71148000
E-mail : info@caplinpoint.net / Website : www.caplinpoint.net
CIN : L24231TN1990PLC019053

ANNEXURE – 5

S. No	Particular	Dr. Sridhar Ganesan	Mr. D. Muralidharan
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Re-appointment of Dr. Sridhar Ganesan (DIN: 06819026) as the Managing Director of the Company	Appointment of Mr. D. Muralidharan (DIN: 08301904) as the Whole-Time Director of the Company
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	August 25, 2026	August 12, 2026
3	Brief profile	Dr. Sridhar Ganesan has over 35 years of global leadership experience in the pharmaceutical industry, with expertise spanning profit centre management, global marketing, international business development, project planning and implementation, production, new product development, quality assurance and factory management. He has held leadership positions across various international assignments, with extensive experience in South Asia, the Middle East and Africa. As Managing Director of the Company, he provides strategic leadership in driving the Company's growth and expanding its global footprint.	Mr. D. Muralidharan has been serving as the Chief Financial Officer (CFO) of the Company since February 19, 2016. He is a seasoned finance professional with rich academic credentials, holding a bachelor's degree in commerce (B. Com), Associate Membership of the Institute of Company Secretaries of India (ICSI), and Cost & Management Accountant qualification from Institute of Cost Accountants of India (ICMAI). He is also a member of the Risk Management Committee of the Company.
4	Disclosure of relationships between directors (in case of appointment of a director).	NIL	Nil

5	Information required pursuant to BSE Circular no. LIST/COMP/14/2018-19 and the NSE Circular no. NSE/ CML/2018/24, both dated 20th June 2018	Dr. Sridhar Ganesan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.	Mr. D. Muralidharan is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.